GLOBAL: Novartis Signs Deal to Provide TB Drugs

Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.

GLOBAL: Novartis Signs Deal to Provide TB Drugs

Associated Press (12.19.03) - Friday, December 19, 2003

Swiss pharmaceuticals manufacturer Novartis signed an agreement today with the World Health Organization to provide free drugs to half a million tuberculosis patients over the next five years. The donation will cost the company $7 million, and it ties in with a campaign by the Global Fund to Fight AIDS, Tuberculosis and Malaria, which has committed $400 million over the past two years to fight TB.

Novartis is one of the world's largest drug companies. It reported a full-year profit of $5.3 billion last year.

TB drugs are well-established and relatively inexpensive. Many people miss out on them, however, due to lack of access to good treatment, according to WHO. The organization calls TB the world's leading curable infectious killer. Almost 2 million people die from TB each year, mainly in Asia, Africa and the former communist bloc.

Novartis plans to buy the drugs from a manufacturer in Bangalore, India, for the Global Drug Facility, a group that organizes bulk procurement of drugs for programs in developing countries. The treatment will be offered as a fixed dose of four drugs in blister packs. This will ensure that more patients take the drugs correctly, thereby reducing the risk of patients developing drug-resistant strains of the disease.

Novartis CEO Daniel Vasella, who had TB as a child, said the donation is designed "to help some of the poorest patients in the world."
031219
AD032639

Copyright © 2003 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.